Windtree Therapeutics Inc WINT shares are trading lower by 6.2% to $7.77 during Monday’s session after the company announced it entered a $1M private placement of Series C Convertible Preferred shares and Warrants.
The company says the funds will be used for working capital and general corporate purposes. The deal is expected to close on July 29, pending customary conditions. The company will seek stockholder approval for the conversion of the Preferred Shares and the exercise of the Warrants into common stock.
During a restricted period, Windtree will not issue any new equity securities without the consent of major security holders. The agreement also includes a participation right for the buyer in future equity placements. The Warrants have an exercise price of $4.11 per share and will become exercisable six months after issuance, expiring five years later.
Read Also: Why Micron Stock Is Volatile This Month
Should I Sell My WINT Stock?
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Windtree Therapeutics have decreased by 70.02% in the past year. An investor who bought shares of Windtree Therapeutics at the beginning of the year would take a loss of $5.07 per share if they sold it today. The stock has risen 134.37% over the past month, meaning an investor who bought shares on Jun. 1 would see a capital gain of $4.0.
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
WINT has a 52-week high of $29.88 and a 52-week low of $2.81.
Read Next:
Image created using artificial intelligence via Midjourney.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.